<div id="readability-page-1"><p>Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been given a consensus recommendation of &#34;Hold&#34; by the twenty-four ratings firms that are currently  covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, ten have given a hold recommendation and eleven have assigned  a buy recommendation to  the company. The average 12-month target price among brokers that have covered the stock in the last year is $18.4348.</p><div><p><span></span><span>Get <strong>Intellia Therapeutics</strong> alerts:</span></p></div><ul><li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li></ul><p>Several brokerages have recently issued reports on NTLA. Barclays dropped their target price on shares of Intellia Therapeutics from $24.00 to $14.00 and set an &#34;overweight&#34; rating on the stock in a research report on Friday, November 7th. Sanford C. Bernstein  set a $14.50 price objective on Intellia Therapeutics in a report on Tuesday, October 28th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Intellia Therapeutics in a research note on Wednesday, October 8th. Wells Fargo &amp; Company reduced their target price on Intellia Therapeutics from $17.00 to $12.00 and set an &#34;equal weight&#34; rating for the company in a report on Friday, November 7th. Finally, Chardan Capital lowered their price target on Intellia Therapeutics from $48.00 to $26.00 and set a &#34;buy&#34; rating on the stock in a research note on Friday, November 7th.</p><p><b>Read Our Latest Analysis on NTLA</b></p><h2>Intellia Therapeutics Trading Up 3.9%</h2><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>Shares of NTLA opened at $9.23 on Friday. The firm has a market cap of $1.07 billion, a P/E ratio of -2.16 and a beta of 2.13. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The stock's 50 day moving average is $12.99 and its two-hundred day moving average is $12.61. </p><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.10. The firm had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The business's revenue was up 51.6% on a year-over-year basis. During the same quarter last year, the firm posted ($1.34) EPS.  Equities research analysts forecast that  Intellia Therapeutics will post -5.07 EPS for the current year. </p><h2>Insiders Place Their Bets</h2><ul><li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li></ul><p>In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer owned 55,266 shares of the company's stock, valued at $960,523.08. The trade was a 3.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own  3.10% of the company's stock. </p><h2>Institutional Trading of Intellia Therapeutics</h2><p>Several large investors have recently bought and sold shares of NTLA. Contrarius Group Holdings Ltd grew its position in shares of  Intellia Therapeutics by 279.4% in the third quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company's stock valued at $101,719,000 after purchasing an additional 4,337,428 shares in the last quarter.  Jupiter Asset Management Ltd. acquired a new position in  Intellia Therapeutics during the third quarter worth $23,519,000.  Marex Group plc acquired a new position in  Intellia Therapeutics during the second quarter worth $5,849,000.  Farallon Capital Management LLC purchased a new stake in  Intellia Therapeutics in the 3rd quarter valued at $10,486,000.  Finally, Vanguard Group Inc. increased its stake in shares of  Intellia Therapeutics by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after acquiring an additional 561,978 shares during the last quarter. Hedge funds and other institutional investors own  88.77% of the company's stock. </p><h2>Intellia Therapeutics Company Profile</h2> (Get Free Report)<p>Intellia Therapeutics, Inc <span>NASDAQ: NTLA<span></span></span> is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.  </p><p>Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Intellia Therapeutics</li><li>Where to Find Earnings Call Transcripts</li><li>These 3 Banks Are Rallying Into Year-End, But Will It Continue?</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>3 Surging Stocks Just Got the Ultimate Stamp of Approval From the S&amp;P 500</li><li>What Investors Need to Know to Beat the Market</li><li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NTLA

<p>Intellia Therapeutics, Inc. (NASDAQ:NTLA) has received a consensus "Hold" recommendation from 24 ratings firms. Analysts have varied opinions, with 3 recommending sell, 10 hold, and 11 buy. The average 12-month target price is $18.43. Recent reports show target price reductions by Barclays, Wells Fargo, and Chardan Capital. The stock opened at $9.23, with a market cap of $1.07 billion. Intellia's revenue increased by 51.6% year-over-year, and insiders own 3.10% of the stock.</p>

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Hold" from Analysts